Effect of Traditional Chinese Medicine Product, QiangGuYin, on Bone Mineral Density and Bone Turnover in Chinese Postmenopausal Osteoporosis

Table 1

Baseline characteristics. There were no significant differences between treatments based on one-way analysis of variance (ANOVA) for continuous variables.

Characteristic	Alendronate; ()	QGY; ()	Placebo; ()
Age (y)	59.8 ± 4.7	58.8 ± 4.4	59.4 ± 4.5
Years since menopause	11.7 ± 5.5	10.5 ± 5.0	11.6 ± 5.7
Height (cm)	156.2 ± 6.6	156.1 ± 6.7	156.1 ± 6.0
Weight (kg)	56.1 ± 8.8	56.1 ± 8.9	56.2 ± 8.8
BMI	22.8 ± 3.2	23.0 ± 3.5	23.0 ± 3.2
BMD (g/cm^2); -score [mean (SD)]
Lumbar spine	0.616 ± 0.049	0.616 ± 0.047	0.615 ± 0.049
	−3.30 ± 0.47	−3.30 ± 0.45	−3.31 ± 0.47
Femoral neck	0.607 ± 0.070	0.606 ± 0.072	0.616 ± 0.064
	−1.91 ± 0.65	−1.92 ± 0.68	−1.83 ± 0.61
Intertrochanter	0.718 ± 0.054	0.720 ± 0.053	0.716 ± 0.053
	−2.23 ± 0.37	−2.22 ± 0.36	−2.25 ± 0.36
Total hip	0.651 ± 0.040	0.650 ± 0.042	0.650 ± 0.042
	−2.11 ± 0.31	−2.11 ± 0.32	−2.10 ± 0.32
Biochemical markers [mean (SE)]
P1NP (ng/ml)	48.60 ± 2.41	47.14 ± 2.31	48.11 ± 2.44
β-CTX (ng/ml)	0.442 ± 0.12	0.437 ± 0.12	0.440 ± 0.12